Effect of Walnuts on Cognitive Function and Gut Microbiome in Older Adults
- Conditions
- AgingInflammation Biomarkers
- Registration Number
- NCT06942351
- Lead Sponsor
- Oregon State University
- Brief Summary
The purpose of this study is to examine the impact of daily consumption of walnuts for 12 weeks on cognitive function, markers of inflammation and oxidative stress, and the gut microbiome in healthy adults age 55 years and older.
- Detailed Description
The investigators will determine the extent to which daily consumption of walnuts by older adults for 12 weeks influences cognitive function and whether improvements are associated with changes in the resident gut microbiota. The investigators propose that age-related cognitive decline can be mitigated by consuming walnuts, by modulating the microbiota and microbial metabolites and decreasing oxidative stress and inflammation.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 80
- Age 55 years or older
- Able to hear well enough to understand spoken instructions and questions
- Able to see well enough to read and respond to printed instructions and fill out questionnaires (corrective lenses are allowed)
- Able to write legibly and move a computer joystick with at least one hand (i.e., no injury or connective tissue or joint disorder that would impair ability to write or make hand movements)
- Able to speak, read, and understand English
- Score of greater than 79 on water maze learning task
- Willing to maintain current eating patterns
- Willing and able to complete the cognitive tests
- Willing to stop consuming almonds, Brazil nuts, cashews, chestnuts, hazelnuts, macadamia nuts, peanuts, pecans, pistachios, walnuts, persimmons and pomegranates for 14 weeks. - are nuts or contain ellagitannins or ellagic acid - compounds/foods of interest for this study
- Willing to limit oak aged wines and spirits to 1 serving/day and limit blackberries (including similar berries like boysenberries, marionberries, and olallieberries), cloudberries, cranberries, currants, elderberries, lingonberries, raspberries, strawberries, wolfberries, other native berries; guava, mango, muscadine grapes, nectarines, peaches, plums, pluots to 1 cup/day for 14 weeks; REMAIN CONSISTENT (consistent intake levels of): Coffee, tea, apple, apricots, blueberries, cherries, grapes (table/common)
- Willing to stop probiotic supplements 2 weeks prior to and during the study (14 weeks)
- Consumption of walnuts, pecans, and chestnuts combined greater than 2 oz / week in the past 3 months.
- Use of oral antibiotics in the past month
- Regular use of oral anti-inflammatory medications in the past month
- Nut, wheat, or gluten allergy/intolerance
- Pregnant or planning to become pregnant during the study period
- Weighs less than 110 pounds
- Diagnosis of sickle cell disease
- Susceptibility to motion sickness
- Consumes 3 or more alcoholic drinks daily
- History of smoking tobacco products, including e-cigarettes and vaporizers in the past 2 years (smokeless tobacco use not exclusionary)
- Use of psilocybin or cannabis products (including CBD-only products) in the past 2 years
- Current treatment for alcohol or other substance use disorder
- History of heart attack, heart failure, or stroke, including transient ischemic attack
- History of liver disease or kidney disease requiring dialysis
- History of cancer in the past 5 years (Skin cancer that was only surgically treated is not exclusionary)
- History of bariatric surgery (e.g., gastric bypass, gastric banding, sleeve gastrectomy, etc.) or disorders (e.g., Crohn's disease, unmanaged celiac disease, ulcerative colitis)
- History of thyroid disorder that requires medication, but subject is not taking medication
- History of chronic bronchitis or emphysema
- Diagnosis of dementia or Alzheimer's disease
- History of head injury requiring hospitalization or loss of consciousness > 5 minutes
- History of chronic migraines (for at least 3 months, headache occurring on 15 or more days per month, where at least 8 of those headache days have migraine symptoms)
- Blood pressure above 159 (systolic) or 99 (diastolic) mm Hg
- Corrected vision worse than 20/50
- Score of less than 10/15 on Ishihara color vision test or diagnosis of color blindness
- Score of less than 26/30 on Mini-Mental State Exam
- Score of greater than 15 on Center for Epidemiologic Depression survey
- History of disease or disorder which causes cognitive impairment, including but limited to: attention-deficit/hyperactivity disorder (ADHD), amyotrophic lateral sclerosis, autism, bipolar disorder, Down's syndrome, encephalitis, epilepsy/seizures, human immunodeficiency virus (HIV), Huntington's disease, Korsakoff's psychosis, multiple sclerosis, Parkinson's disease, or psychotic disorders (e.g., schizophrenia, schizoaffective disorder, schizophreniform disorder)
- Current and regular use of any of the following medications: insulin, opioids, anti-seizure medications, psychotropic medications: stimulants, anti-psychotics, or medications that cause daytime drowsiness or difficulty concentrating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Cognitive function - memory 0 and 12 weeks Change from baseline at week 12: proximity (lower score reflects positive outcome)
Cognitive function - cognitive flexibility 0 and 12 weeks Change from baseline at week 12: proximity (lower score reflects positive outcome)
Cognitive function - speed of processing 0 and 12 weeks Change from baseline at week 12: age adjusted standard scores (higher score reflects positive outcome)
Gut microbiome composition 0 and 12 weeks Change from baseline at week 12: microbiome composition
Lipid oxidation levels 0 and 12 weeks Change from baseline at week 12: plasma malondialdehyde (MDA)
Gut permeability and health: Inflammatory biomarkers 0 and 12 weeks Change from baseline at week 12: Gut inflammatory biomarkers fecal calprotectin and myeloperoxidase
Biomarkers of inflammation 0 and 12 weeks Change from baseline at week 12: Plasma inflammatory markers (ex. CRP and IL-6)
- Secondary Outcome Measures
Name Time Method Urolithin concentrations 0 and 12 weeks Change from baseline at week 12: urolithin A and urolithin B concentrations in urine
Blood pressure 0 and 12 weeks Change from baseline at week 12: systolic and diastolic blood pressure
Weight 0 and 12 weeks Change from baseline at week 12: weight
Trial Locations
- Locations (1)
Oregon State University
🇺🇸Corvallis, Oregon, United States